QNCX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Quince Therapeutics Inc (QNCX) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company has faced significant setbacks, including the failure of its pivotal Phase 3 NEAT clinical trial, which has led to multiple analyst downgrades and a lack of positive catalysts. The technical indicators are bearish, and there is no signal from Intellectia Proprietary Trading Signals to suggest an opportunity. The financial performance is weak, with no revenue and significant losses. Given the lack of growth potential and negative sentiment, selling or avoiding this stock is recommended.
The MACD is positive and expanding (0.0801), but the RSI at 28.526 is neutral and does not indicate a strong entry point. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below key support levels (S1: 0.128). Overall, the technical indicators suggest a bearish trend.
NULL identified. No recent news or events suggest a positive outlook for the stock.
Additionally, the stock is trading below its cash levels, indicating a lack of investor confidence.
The company's financials for 2025/Q3 show no revenue growth (0% YoY), a net income loss of -$13.44 million (up 144.76% YoY), and an EPS of -0.25 (up 92.31% YoY). Gross margin remains at 0%. Overall, the financial performance is weak, with no signs of growth or profitability.
Analysts have overwhelmingly downgraded the stock following the failure of the Phase 3 trial. Lucid Capital assigned a price target of $0, and other firms have downgraded the stock to Hold or Sell. The sentiment is highly negative, with no positive outlook from analysts.
